The study had important limitations, including the small number of patients and the lack of a control group that was followed with standard therapy to compare benefits and side effects.

WSJ: New Strategies for Treating Diabetes

In stark contrast to ImClone, which rashly tested Erbitux in only 120 patients with no control group, AstraZeneca enrolled 2, 000 patients in late-stage trials to compare how long patients survive on a combination of chemotherapy and Iressa versus chemo and a placebo.

FORBES: Modesty ablaze